Quick Answer
Dogwood Therapeutics, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2025.
Dogwood Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$7.13 | +43.1% |
| 2024 | -$12.52 | -77.6% |
| 2023 | -$7.05 | -535.1% |
| 2022 | -$1.11 | +42.2% |
| 2021 | -$1.92 | +8.6% |
| 2020 | -$2.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.20 | -300.0% | -312.1% |
| June 30, 2025 | -$1.99 | -73.0% | +76.4% |
| March 31, 2025 | -$8.45 | -403.0% | -312.2% |
| September 30, 2024 | -$2.05 | -26.5% | -78.3% |
| June 30, 2024 | -$1.15 | -1337.5% | +31.5% |
| March 31, 2024 | -$1.68 | -2000.0% | -3.7% |
| September 30, 2023 | -$1.62 | -478.6% | -1925.0% |
| June 30, 2023 | -$0.08 | +81.8% | +0.0% |
- Dogwood Therapeutics, Inc. showed an increase of +43.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Dogwood Therapeutics, Inc.’s diluted eps has declined by 239.5% (from $2.10 per share (loss) to $7.13 per share (loss)).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: